Eckert & Ziegler SE (EUZ.DE) stock: Winston Score, insiders and Congress trades

Eckert & Ziegler is a German company that makes radioactive materials used in medicine and industry. Its main products are radioisotopes — tiny amounts of radioactive substances used to treat cancer, diagnose diseases, and calibrate scientific equipment. Its customers include hospitals, cancer treatment centers, pharmaceutical companies, and research labs around the world. The company earns money by producing and selling these radioactive materials, along with related devices and services. It operates primarily in Europe and North America, with a growing presence in other markets, and generates roughly €250–300 million in annual revenue. Its moat comes from the highly regulated nature of radioactive material production — getting government licenses to handle and ship these substances takes years, which keeps most competitors out. The key growth driver is the fast-expanding field of radioligand therapy, a cancer treatment method that uses targeted radioactive molecules, where Eckert & Ziegler is positioned as a supplier of critical isotope ingredients.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-12.